Hyderabad, April 2025: We are pleased to share that Vigilare BioPharma was announced as an aspirant in the Everest Group PEAK Matrix for Post-approval Pharmacovigilance (PV) Operations 2025. The recognition clearly acknowledges our growing presence and expertise in the Pharmacovigilance landscape, and we are glad to be able to compete with some of the industry bigwigs. Step by step, Vigilare is set to redefine the PV operations landscape.
Everest PEAK Matrix had chosen Vigilare BioPharma as an aspirant in a few considerations, such as:
- Targeted pharmacovigilance (PV) services
- Exclusive focus on selected buyer segments and therapeutic areas
- PV service provision for a specific regional market
Being acknowledged as an aspirant, Mr.Praneeth kamishetty, CEO of Vigilare BioPharma, shares that “this recognition clearly reflects our strong foundation, growing market presence, and commitment to quality-driven, tech-enabled pharmacovigilance (PV) solutions.”
“This recognition not only fuels our commitment for the pharmacovigilance landscape, but also sets our path ahead, i.e., to aim for a major contender in the next phase of Everest PEAK Matrix for Post-approval PV Operations. We are looking forward to driving this momentum with scalable global delivery capabilities, flexible and compliant post-marketing PV models,” Praneeth added.
About Vigilare BioPharma:
Vigilare Biopharma is a fast-growing, ISO-certified Clinical Research Organization (CRO) focused on the safety assessment and regulatory compliance of drug products. Backed by years of expertise in Life Sciences and MedTech and with a deep understanding of global health authority procedures, including US FDA, EMA, CDSCO, and more, we support the development of safe, effective, and trusted medicines and medical products for global markets.
Vigilare BioPharma’s goal is to promote the safe and effective use of pharmaceutical products and to ensure that patients receive the highest quality of care.
Comments are closed